57.48MMarket Cap-2423P/E (TTM)
13.5700High12.6000Low27.81KVolume13.3200Open13.0500Pre Close360.52KTurnover0.72%Turnover RatioLossP/E (Static)4.56MShares29.600052wk High-7.00P/B48.88MFloat Cap10.000052wk Low--Dividend TTM3.88MShs Float382.6000Historical High--Div YieldTTM7.43%Amplitude8.0000Historical Low12.9630Avg Price1Lot Size
Cidara Therapeutics Stock Forum
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
Larger Image: tradingview.com...
$Cidara Therapeutics(CDTX.US)$
Hopefully it'll continue to run tomorrow?
WSJ· 4 mins ago
Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment.
The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
Cidara Therapeutics-Under Deal,Future Royalties & Milestones From Mundipharma,Melinta Therapeutics Previously Payable to Co to Transfer t...
NEWS
Cidara Therapeutics Announces Reverse Stock Split
Cidara Therapeutics, a biotechnology company, announced a 1-for-20 reverse stock split of its common stock. The reverse split will be effective on April 23, 2024, with trading on a split-adjusted basis starting on April 24, 2024. This decision was made following a stockholder vote and board approval to enhance the stock's value and reduce the number of outstanding shares.
No comment yet